公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2017 | Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry | Gautschi O.; Milia J.; Filleron T.; Wolf J.; Carbone D.P.; Owen D.; Camidge R.; Narayanan V.; Doebele R.C.; Besse B.; Remon-Masip J.; Janne P.A.; Awad M.M.; Peled N.; Byoung C.-C.; Karp D.D.; Van Den Heuvel M.; Wakelee H.A.; Neal J.W.; Mok T.S.K.; CHIH-HSIN YANG ; Ou S.-H.I.; Pall G.; Froesch P.; Zalcman G.; Gandara D.R.; Riess J.W.; Velcheti V.; Zeidler K.; Diebold J.; Früh M.; Michels S.; Monnet I.; Popat S.; Rosell R.; Karachaliou N.; Rothschild S.I.; JIN-YUAN SHIH ; Warth A.; Muley T.; Cabillic F.; Mazières J.; Drilon A. | Journal of Clinical Oncology | 278 | 249 | |
2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer | Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG ; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. | EMBO Molecular Medicine | 38 | 34 | |
2020 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer | Oxnard G.R.; CHIH-HSIN YANG ; Yu H.; Kim S.-W.; Saka H.; Horn L.; Goto K.; Ohe Y.; Mann H.; Thress K.S.; Frigault M.M.; Vishwanathan K.; Ghiorghiu D.; Ramalingam S.S.; Ahn M.-J. | Annals of Oncology | 272 | 228 | |
2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice | Le, Xiuning; Sakai, Hiroshi; Felip, Enriqueta; Veillon, Remi; Garassino, Marina Chiara; Raskin, Jo; Cortot, Alexis B; Viteri, Santiago; Mazieres, Julien; Smit, Egbert F; Thomas, Michael; Iams, Wade T; Cho, Byoung Chul; Kim, Hye Ryun; CHIH-HSIN YANG ; Chen, Yuh-Min; Patel, Jyoti D; Bestvina, Christine M; Park, Keunchil; Griesinger, Frank; Johnson, Melissa; Gottfried, Maya; Britschgi, Christian; Heymach, John; Sikoglu, Elif; Berghoff, Karin; Schumacher, Karl-Maria; Bruns, Rolf; Otto, Gordon; Paik, Paul K | Clinical cancer research : an official journal of the American Association for Cancer Research | 48 | 39 | |
2020 | Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations | Paik P.K.; Felip E.; Veillon R.; Sakai H.; Cortot A.B.; Garassino M.C.; Mazieres J.; Viteri S.; Senellart H.; van Meerbeeck J.; Raskin J.; Reinmuth N.; Conte P.; Kowalski D.; Cho B.C.; Patel J.D.; Horn L.; Griesinger F.; Han J.-Y.; Kim Y.-C.; Chang G.-C.; Tsai C.-L.; CHIH-HSIN YANG ; Chen Y.-M.; Smit E.F.; van der Wekken A.J.; Kato T.; Juraeva D.; Stroh C.; Bruns R.; Straub J.; Johne A.; Scheele J.; Heymach J.V.; Le X. | New England Journal of Medicine | 475 | 409 | |
2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 161 | 128 | |
2023 | Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial | Mazieres, Julien; Paik, Paul K; Garassino, Marina C; Le, Xiuning; Sakai, Hiroshi; Veillon, Remi; Smit, Egbert F; Cortot, Alexis B; Raskin, Jo; Viteri, Santiago; Wu, Yi-Long; CHIH-HSIN YANG ; Ahn, Myung-Ju; Ma, Rui; Zhao, Jun; O'Brate, Aurora; Berghoff, Karin; Bruns, Rolf; Otto, Gordon; Johne, Andreas; Felip, Enriqueta; Thomas, Michael | JAMA oncology | 9 | 4 | |
2005 | Third-line chemotherapy for advanced non-small-cell lung cancer - Is there enough evidence to support its use? | CHIH-HSIN YANG | Journal of the Chinese Medical Association | 1 | 0 | |
2006 | Thoracic radiotherapy for stage IV non-small cell lung cancer [4] | Chien C.-R; CHIH-HSIN YANG | Radiotherapy and Oncology | 0 | 0 | |
2011 | Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed | CHUNG-YU CHEN ; YIH-LEONG CHANG ; JIN-YUAN SHIH ; JOU-WEI LIN ; KUAN-YU CHEN ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Lung Cancer | 108 | 102 | |
2019 | Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies | Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG ; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I. | Lung Cancer: Targets and Therapy | 3 | 1 | |
2022 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | Cho, Byoung Chul; Abreu, Delvys Rodriguez; Hussein, Maen; Cobo, Manuel; Patel, Anjan J; Secen, Nevena; Lee, Ki Hyeong; Massuti, Bartomeu; Hiret, Sandrine; CHIH-HSIN YANG ; Barlesi, Fabrice; Lee, Dae Ho; Ares, Luis Paz; Hsieh, Robert W; Patil, Namrata S; Twomey, Patrick; Yang, Xiaoying; Meng, Raymond; Johnson, Melissa L | The Lancet. Oncology | 142 | 133 | |
2024 | Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer | YEN-TING LIN ; CHAO-CHI HO ; Hsu, Wei-Hsun; WEI-YU LIAO ; CHING-YAO YANG ; CHONG-JEN YU ; TZU-HSIU TSAI ; CHIH-HSIN YANG ; SHANG-GIN WU ; CHIA-LIN HSU ; Hsieh, Min-Shu; YEN-LIN HUANG ; Wu, Chia-Ling; JIN-YUAN SHIH | Cancer medicine | 0 | | |
2008 | Translation and cultural adaptation of the patient disease and treatment assessment form: A novel quality of life instrument for use in Taiwan | Gainford M.C; CHIH-HSIN YANG ; Liu M.-Y; Stockler M. | Asia-Pacific Journal of Clinical Oncology | 0 | 0 | |
2023 | Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial | Goto, Koichi; Goto, Yasushi; Kubo, Toshio; Ninomiya, Kiichiro; Kim, Sang-We; Planchard, David; Ahn, Myung-Ju; Smit, Egbert F; de Langen, Adrianus Johannes; Pérol, Maurice; Pons-Tostivint, Elvire; Novello, Silvia; Hayashi, Hidetoshi; Shimizu, Junichi; Kim, Dong-Wan; Kuo, Chih-Hsi; CHIH-HSIN YANG ; Pereira, Kaline; Cheng, Fu-Chih; Taguchi, Ayumi; Cheng, Yingkai; Feng, Wenqin; Tsuchihashi, Zenta; Jänne, Pasi A | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 16 | 3 | |
2018 | Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Opinion on Pharmacotherapy | 5 | 5 | |
2015 | Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy | BIN-CHI LIAO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG | Therapeutic Advances in Medical Oncology | 16 | 16 | |
2014 | Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International expert panel meeting of the Italian association of thoracic oncology | Gridelli C; De Marinis F; Cappuzzo F; Di Maio M; Hirsch F.R; Mok T; Morgillo F; Rosell R; Spigel D.R; CHIH-HSIN YANG ; Ciardiello F. | Clinical Lung Cancer | 57 | 55 | |
2021 | Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial | Zhou C.; Ramalingam S.S.; Kim T.M.; Kim S.-W.; CHIH-HSIN YANG ; Riely G.J.; Mekhail T.; Nguyen D.; Garcia Campelo M.R.; Felip E.; Vincent S.; Jin S.; Griffin C.; Bunn V.; Lin J.; Lin H.M.; Mehta M.; J?nne P.A. | JAMA Oncology | 163 | 127 | |
2023 | TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC | Levy, Benjamin P; Felip, Enriqueta; Reck, Martin; CHIH-HSIN YANG ; Cappuzzo, Federico; Yoneshima, Yasuto; Zhou, Caicun; Rawat, Siddhartha; Xie, Jingdong; Basak, Priyanka; Xu, Lu; Sands, Jacob | Future oncology (London, England) | 2 | 1 | |